Induction of heparanase-1 expression by mutant B-Raf kinase: Role of GA binding protein in heparanase-1 promoter activation

Neoplasia

Volumn 12, Issue 11, 2010, Pages 946-956

  Rao, Geetha ^a   Liu, Dingxie ^b   Xing, Mingzhao ^b   Tauler, Jordi ^a   Prinz, Richard A ^a   Xu, Xiulong ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GA BINDING PROTEIN; HEPARANASE; HEPARANASE 1; HEPARIN; LUCIFERASE; PI 88; RAS PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE EXPRESSION; GENE INDUCTION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MUTANT; ONCOGENE; ONCOGENE BRAF; ONCOGENE HPR1; ONCOGENE RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 78449263436     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10790     Document Type: Article

References (52)

1. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, et al. (1999). Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 5, 793-802.
2. Vlodavsky I and Friedmann Y (2001). Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108, 341-347.
3. Hulett M, Freeman C, Hamdorf B, Baker R, Harris M, and Parish C (1999). Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 5, 803-809.
4. Parish CR, Freeman C, and Hulett MD (2001). Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 1471, M99-M108.
5. Zetser A, Bashenko Y, Miao HQ, Vlodavsky I, and Ilan N (2003). Heparanase affects adhesive and tumorigenic potential of human glioma cells. Cancer Res 63, 7733-7741.
6. Goldshmidt O, Zcharia E, Cohen M, Aingorn H, Cohen I, Nadav L, Katz BZ, Geiger B, and Vlodavsky I (2003).Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J 17, 1015-1025.
7. Zetser A, Bashenko Y, Edovitsky E, Levy-Adam F, Vlodavsky I, and Ilan N (2006). Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 66, 1455-1463.
8. Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I, and Doweck I (2008). Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 123, 2566-2573.
9. Cohen-Kaplan V, Doweck I, Naroditsky I, Vlodavsky I, and Ilan N (2008). Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res 68, 10077-10085.
10. Lai NS, Simizu S, Morisaki D, Muroi M, and Osada H (2008). Requirement of the conserved, hydrophobic C-terminus region for the activation of heparanase. Exp Cell Res 314, 2834-2845.
11. Fux L, Feibish N, Cohen-Kaplan V, Gingis-Velitski S, Feld S, Geffen C, Vlodavsky I, and Ilan N (2009). Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res 69, 1758-1767.
12. Lu WC, Liu YN, Kang BB, and Chen JH (2003). Trans-activation of heparanase promoter by ETS transcription factors. Oncogene 22, 919-923.
13. Jiang P, Kumar A, Parrillo JE, Dempsey LA, Platt JL, Prinz RA, and Xu X (2002). Cloning and characterization of the human heparanase 1 (HPR1) gene promoter: role of GA-binding protein and Sp1 in regulating HPR1 basal promoter activity. J Biol Chem 277, 8989-8998.
14. de Mestre AM, Rao S, Hornby JR, Soe-Htwe T, Khachigian LM, and Hulett MD (2005). Early growth response gene 1 (EGR1) regulates heparanase gene transcription in tumor cells. J Biol Chem 280, 35136-35147.
15. de Mestre AM, Khachigian LM, Santiago FS, Staykova MA, and Hulett MD (2003). Regulation of inducible heparanase gene transcription in activated T cells by early growth response 1. J Biol Chem 278, 50377-50385.
16. Ogishima T, Shiina H, Breault JE, Terashima M, Honda S, Enokida H, Urakami S, Tokizane T, Kawakami T, Ribeiro-Filho LA, et al. (2005). Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene 24, 6765-6772.
17. Ogishima T, Shiina H, Breault JE, Tabatabai L, Bassett WW, Enokida H, Li LC, Kawakami T, Urakami S, Ribeiro-Filho LA, et al. (2005). Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res 11, 1028-1036.
18. Baraz L, Haupt Y, Elkin M, Peretz T, and Vlodavsky I (2006). Tumor suppressor p53 regulates heparanase gene expression. Oncogene 25, 3939-3947.
19. Michaloglou C, Vredeveld LC, Mooi WJ, and Peeper DS (2008). BRAF(E600) in benign and malignant human tumours. Oncogene 27, 877-895.
20. Xu X, Quiros RM, Gattuso P, Ain KB, and Prinz RA (2003). High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 63, 4561-4567.
21. Xu X, Quiros RM, Maxhimer JB, Jiang P, Marcinek R, Ain KB, Platt JL, Shen J, Gattuso P, and Prinz RA (2003). Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res 9, 5968-5979.
22. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
23. Li XR, Chong AS, Wu J, Roebuck KA, Kumar A, Parrillo JE, Rapp UR, Kimberly RP, Williams JW, and Xu X (1999). Transcriptional regulation of Fas gene expression by GA-binding protein and AP-1 in T cell antigen receptor·CD3 complex-stimulated T cells. J Biol Chem 274, 35203-35210.
24. Liu D, Liu Z, Condouris S, and Xing M (2007). BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 92, 2264-2271.
25. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow L, Copland JA, Smallridge RC, et al. (2008). Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals crosscontamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93, 4331-4341.
26. Eustice DC, Feldman PA, Colberg-Poley AM, Buckery RM, and Neubauer RH (1991). A sensitive method for the detection of beta-galactosidase in transfected mammalian cells. Biotechniques 11, 739-740, 742-743.
27. Xu X, Ding J, Rao G, Shen J, Prinz RA, Rana N, and Dmowski WP (2007). Estradiol induces heparanase-1 expression and heparan sulphate proteoglycan degradation in human endometrium. Hum Reprod 22, 927-937.
28. Xu X, Rao G, Quiros RM, Kim AW, Miao HQ, Brunn GJ, Platt JL, Gattuso P, and Prinz RA (2007). In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas. Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation. J Biol Chem 282, 2363-2373.
29. Maxhimer JB, Somenek M, Rao G, Pesce CE, Baldwin D Jr, Gattuso P, Schwartz MM, Lewis EJ, Prinz RA, and Xu X (2005). Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes 54, 2172-2178.
30. Quiros RM, Rao G, Plate J, Harris JE, Brunn GJ, Platt JL, Gattuso P, Prinz RA, and Xu X (2006). Elevated serum heparanase-1 levels in patients with pancreatic carcinoma are associated with poor survival. Cancer 106, 532-540.
31. Ihrcke NS, Parker W, Reissner KJ, and Platt JL (1998). Regulation of platelet heparanase during inflammation: role of pHand proteinases. J Cell Physiol 175, 255-267.
32. Turner DP and Watson DK (2008). ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev Anticancer Ther 8, 33-42.
33. de Launoit Y, Baert JL, Chotteau-Lelievre A, Monte D, Coutte L, Mauen S, Firlej V, Degerny C, and Verreman K (2006). The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim Biophys Acta 1766, 79-87.
34. Valouev A, Johnson DS, Sundquist A, Medina C, Anton E, Batzoglou S, Myers RM, and Sidow A (2008). Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data. Nat Methods 5, 829-834.
35. Fowles LF, Martin ML, Nelsen L, Stacey KJ, Redd D, Clark YM, Nagamine Y, McMahon M, Hume DA, and Ostrowski MC (1998). Persistent activation of mitogen-activated protein kinases p42 and p44 and ets-2 phosphorylation in response to colony-stimulating factor 1/c-fms signaling. Mol Cell Biol 18, 5148-5156.
36. Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H, Chong JL, et al. (2009). Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 461, 1084-1091.
37. McCarthy SA, Chen D, Yang BS, Garcia Ramirez JJ, Cherwinski H, Chen XR, Klagsbrun M, Hauser CA, Ostrowski MC, and McMahon M (1997). Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1. Mol Cell Biol 17, 2401-2412.
38. Hoffmeyer A, Avots A, Flory E, Weber CK, Serfling E, and Rapp UR (1998). The GABP-responsive element of the inerleukin-2 enhancer is regulated by JNK/ SAPK-activating pathways in T lymphocytes. J Biol Chem 273, 10112-10119.
39. Flory E, Hoffmeyer A, Smola U, Rapp UR, and Bruder JT (1996). Raf-1 kinase targets GA-binding protein in transcriptional regulation of the human immunodeficiency virus type 1 promoter. J Virol 70, 2260-2268.
40. Fromm L and Burden SJ (2001). Neuregulin-1-stimulated phosphorylation of GABP in skeletal muscle cells. Biochemistry 40, 5306-5312.
41. Herndon CA and Fromm L (2008).Neuregulin-1 induces acetylcholine receptor transcription in the absence of GABPalpha phosphorylation. J Neurosci Res 86, 982-991.
42. Atlas E, Stramwasser M, and Mueller CR (2001). A CREB site in the BRCA1 proximal promoter acts as a constitutive transcriptional element. Oncogene 20, 7110-7114.
43. Hoare S, Copland JA, Wood TG, Jeng YJ, Izban MG, and Soloff MS (1999). Identification of a GABP alpha/beta binding site involved in the induction of oxytocin receptor gene expression in human breast cells, potentiation by c-Fos/ c-Jun. Endocrinology 140, 2268-2279.
44. Schweppe RE, Melton AA, Brodsky KS, Aveline LD, Resing KA, Ahn NG, and Gutierrez-Hartmann A (2003). Purification and mass spectrometric identification of GA-binding protein (GABP) as the functional pituitary Ets factor binding to the basal transcription element of the prolactin promoter. J Biol Chem 278, 16863-16872.
45. Safe S and Abdelrahim M (2005). Sp transcription factor family and its role in cancer. Eur J Cancer 41, 2438-2448.
46. Xing M (2007). BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28, 742-762.
47. Gaggioli C, Robert G, Bertolotto C, Bailet O, Abbe P, Spadafora A, Bahadoran P, Ortonne JP, Baron V, Ballotti R, et al. (2007). Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. J Invest Dermatol 127, 400-410.
48. Liang S, Sharma A, Peng HH, Robertson G, and Dong C (2007). Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res 67, 5814-5820.
49. Sharma A, Tran MA, Liang S, Sharma AK, Amin S, Smith CD, Dong C, and Robertson GP (2006). Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res 66, 8200-8209.
50. Huntington JT, Shields JM, Der CJ, Wyatt CA, Benbow U, Slingluff CL Jr, and Brinckerhoff CE (2004). Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem 279, 33168-33176.
51. Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, and Fagin JA (2006). Conditional activation of RET/ PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res 66, 6521-6529.
52. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, and Robertson GP (2005). Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65, 2412-2421.